Response

Affiliations

Comment

Maureen Trudeau. J Natl Cancer Inst. 2016.

. 2016 Jul 4;108(8):djw105.

doi: 10.1093/jnci/djw105. Print 2016 Aug.

¹ Sunnybrook Odette Cancer Centre, 2075 Bayview Ave, Toronto, ON Canada M4N 3M5. maureen.trudeau@sunnybrook.ca.

No abstract available

Comment on

RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy.
Pritzker K, Pritzker L, Generali D, Bottini A, Cappelletti MR, Guo B, Parissenti A, Trudeau M. Pritzker K, et al. J Natl Cancer Inst Monogr. 2015 May;2015(51):76-80. doi: 10.1093/jncimonographs/lgv015. J Natl Cancer Inst Monogr. 2015. PMID: 26063893
RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Toomey S, Eustace AJ, Pritzker LB, Pritzker KP, Fay J, O'Grady A, Cummins R, Grogan L, Kennedy J, O'Connor D, Young L, Kay EW, O'Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy BT. Toomey S, et al. J Natl Cancer Inst. 2016 Jul 4;108(8):djw111. doi: 10.1093/jnci/djw111. Print 2016 Aug. J Natl Cancer Inst. 2016. PMID: 27377904 Free PMC article. No abstract available.

1. Crown J, Coate L, Keane M, et al. Randomized phase II study of pre-operative docetaxel, carboplatin with trastuzumab (TCH) and/or/lapatinib (L) in HER-2 positive (H+) breast cancer patients (BCpts). ICORG 10-05. Cancer Res. 2013;73(24 Suppl):Abstract nr P4-12-25.
1. Parissenti AM, Chapman JA, Kahn HJ, et al. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2010;119(2):347–356. - PubMed
1. Parissenti AM, Guo B, Pritzker LB, et al. Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy. Breast Cancer Res Treat. 2015;153(1):134–144. - PubMed
1. Trudeau ME, Chapman JA, Guo B, et al. A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22. Springerplus. 2015;4:631. - PMC - PubMed